The effect of high glucose and PPAR-γ agonists on PPAR-γ expression and function in HK-2 cells

American Journal of Physiology - Renal Physiology

Volumn 287, Issue 3 56-3, 2004, Pages

  Panchapakesan, U ^a   Pollock, C A ^a,b   Chen, X M ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b ROYAL NORTH SHORE HOSPITAL   (Australia)

Author keywords

Cell cycle; Diabetic nephropathy; Proximal tubular cells; Thiazolidinediones

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; GLUCOSE; L 805645; MONOCYTE CHEMOTACTIC PROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PIOGLITAZONE; THYMIDINE; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL CYCLE G1 PHASE; CELL GROWTH; CELL LINE; CELL VIABILITY; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DRUG EFFECT; DRUG MECHANISM; FLOW CYTOMETRY; HUMAN; HUMAN TISSUE; INFLAMMATION; INSULIN SENSITIVITY; KIDNEY PROXIMAL TUBULE; LIPID METABOLISM; MITOSIS INHIBITION; PRIORITY JOURNAL;

EID: 4143099046     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00445.2003     Document Type: Article

References (34)

1. Amann B, Tinzmann R, and Angelkort B. ACE inhibitors improve diabetic nephropathy through suppression of renal MCP-1. Diabetes Care 26: 2421-2425, 2003.
2. Arici M, Chana R, Lewington A, Brown J, and Brunskill NJ. Stimulation of proximal tubular cell apoptosis by albumin-bound fatty acids mediated by peroxisome proliferator activated receptor-γ. J Am Soc Nephrol 14: 17-27, 2003.
3. Asano T, Wakisaka M, Yoshinari M, Iino K, Sonoki K, Iwase M, and Fujishima M. Peroxisome proliferator-accivaced receptor γ1 (PPAR-γ1) expresses in rat mesangial cells and PPAR-γ agonists modulate its differentiation. Biochim Biophys Acta 1497: 148-154, 2000.
4. Baumgartl HJ, Sigl G, Banholzer P, Haslheck M, and Standl E. On the prognosis of IDDM patients with large kidneys. Nephrol Dial Transplant 13: 630-634, 1998.
5. Berger J and Wagner JA. Physiological and therapeutic roles of peroxisome proliferator-activated receptors. Diabetes Technol Ther 4: 163-174, 2002.
6. Buckingham RE, Al-Barazanji KA, Toseland CD, Slaughter M, Connor SC, West A, Bond B, Turner NC, and Clapham JC. Peroxisome proliferator-activated receptor-γ agonist, rosiglitazone, protects against nephropathy and pancreatic islet abnormalities in Zucker fatty rats. Diabetes 41: 1326-1334, 1998.
7. Chen J, Sun Z, Ma J, Gu Y, Yang H, and Lin S. Nonmetabolic protective effects of pioglitazone on diabetic nephropathy induced by streptozotocin in uninephrectomized rat (Abstract). J Am Soc Nephrol 14: 392A, 2003.
8. Dehril MB, Renaud JP, Fajas L, and Auwerx J. The pleiotropic functions of peroxisome proliferator-activated receptor γ. J Mol Med 79: 30-47, 2001.
9. +-exchanger isoform 3 in OK cells. Cell Physiol Biochem 13: 199-206, 2003.
10. Forman BM, Tontonoz P, Chen J, Brun RP, Spiegelman BM, and Evans RM. 15-Deoxy-Δ12,14-prostaglandin J2 is a ligand for the adipocyte determination factor PPARγ. Cell 83: 803-812, 1995.
11. Ghosh SS, Gehr TW, Ghosh S, Fakhry I, Sica DA, Lyall V, and Schoolwerth AC. PPARγ ligand attenuates PDGF-induced mesangial cell proliferation: role of MAP kinase. Kidney Int 64: 52-62, 2003.
12. Guan Y, Zhang Y, and Breyer MD. The role of PPARs in the transcriptional control of cellular processes. Drug News Perspect 15: 147-154, 2002.
13. Harper JW, Elledge SJ, Keyomarsi K, Dynlacht B, Tsai LH, Zhang P, Dobrowolski S, Bai C, Connell-Crowley L, Swindell E, Fox MP, and Wei N. Inhibition of cyclin-dependent kinases by p21. Mol Biol Cell 6: 387-400, 1995.
14. Imano E, Kanda T, Nakatani Y, Nishida T, Arai K, Motomura M, Kajimoto Y, Yamasaki Y, and Hori M. Effect of trogtitazone on microalbuminuria in patients with incipient diabetic nephropathy. Diabetes Care 21: 2135-2139, 1998.
15. Kato S, Luyckx VA, Ots M, Lee KW, Ziai F, Troy JL, Brenner BM, and MacKenzie HS. Renin-angiotensin blockade lowers MCP-1 expression in diabetic rats. Kidney Int 56: 1037-1048, 1999.
16. Kliewer SA, Lenhard JM, Willson TM, Patel I, Morris DC, and Lehmann JM. A prostaglanilin J2 metabolite binds peroxisome proliferator-activated receptor γ and promotes adipocyte differentiation. Cell 83: 813-819, 1995.
17. Lee EM, Pollock CA, Drumm K, Barden JA, and Poronnik P. Effects of pathophysiological concentrations of albumin on NHE3 activity and cell proliferation in primary cultures of human proximal tubule cells. Am J Physiol Renal Physiol 285: F748-F757, 2003.
18. Ma LJ, Marcantoni C, Linton MF, Fazio S, and Fogo AB. Peroxisome proliferator-activated receptor-γ agonist troglitazone protects against non-diabetic glomerulosclerosis in rats. Kidney Int 59: 1899-1910, 2001.
19. McCarthy KJ, Routh RE, Shaw W, Walsh K, Welhourne TC, and Johnson JH. Troglitazone halts diabetic glomerulosclerosis by blockade of mesangial expansion. Kidney Int 58: 2341-2350, 2000.
20. Miyata KS, McCaw SE, Marcus SL, Radmbinski RA, and Capone JP. The peroxisome proliferator-activated receptor interacts with the retinoid X receptor in vivo. Gene 148: 327-330, 1994.
21. Nagy L, Tontonoz P, Alvarez JG, Chen H, and Evans RM. Oxidized LDL regulates macrophage gene expression through ligand activation of PPARγ. Cell 93: 229-240. 1998.
22. Nath KA. Tubulointerstitial changes as a major determinant in the progression of renal damage. Am J Kidney Dis 20: 1-17, 1992.
23. Nicholas SB, Kawano Y, Wakino S, Collins AR, and Hsueh WA. Expression and function of peroxisome proliferator-activated receptor-γ in mesangial cells. Hypertension 37: 722-727, 2001.
24. Parameswaran N, Hall CS, Bomberger JM, Sparks HV, Jump DB, and Spielman WS. Negative growth effects of ciglitazone on kidney interstitial fibroblasts: role of PPAR-γ. Kidney Blood Press Res 26: 2-9. 2003.
25. Ping D, Boekhoudt GH, Rogers EM, and Boss JM. Nuclear factor-κB p65 mediates the assembly and activation of the TNF-responsive element of the murine monocyte chemoattractant-1 gene. J Immunol 162: 727-734, 1999.
26. Routh RE, Johnson JH, and McCarthy KJ. Troglitazone suppresses the secretion of type 1 collagen by mesangial cells in vitro. Kidney Int 61: 1365-1376, 2002.
27. Tontonoz P, Nagy L, Alvarez JG, Thomazy VA, and Evans RM. PPARγ promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell 93: 241-252, 1998.
28. US Renal Data System. Annual Data Report: Atlas of End-Stage Renal Disease in the United States, National Institute Diabetes and Digestive and Kidney Diseases. Bethesda, MD, 2003.
29. Wada T, Furuichi K, Sakai N, Iwata Y, Yoshimoto K, Shimizu M, Takeda SI, Takasawa K, Yoshimura M, Kida H, Kobayashi KI, Mukaida N, Naito T, Matsushima K, and Yokoyama H. Upregulation of monocyte chemoattractant protein-1 in tubulointerstitial lesions of human diabetic nephropathy. Kidney Int 58: 1492-1499, 2000.
30. 1: inhibition of high glucose-induced promoter activity by thiazotidinediones. Biochem Biophys Res Commun 304: 301-307, 2003.
31. Wolf G and Ziyadeh FN. Molecular mechanisms of diabetic renal hypertrophy. Kidney Int 56: 393-405, 1999.
32. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, and Beach D. p21 Is a universal inhibitor of cyclin kinases. Nature 366: 701-704, 1993.
33. Zafiriou S, Stanners SS, Polhill TS, Poronnik P, and Pollock CA. Pioglitazone increases renal tubular cell uptake but limits proinflammalory and fibrotic responses. Kidnev Int 65: 1647-1653, 2004.
34. Zhang Y, Park CW, Zheng F, Fan X, Striker GE, Breyer MD, and Guan Y. Endogenous PPAR-γ activity ameliorates diabetic nephropathy (Abstract). J Am Soc Nephrol 14: 392A, 2003.